AGIO

Company Overview — What Does AGIOS PHARMACEUTICALS, INC. Do?

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. AGIOS PHARMACEUTICALS, INC. (AGIO) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Brian M. Goff and employs approximately 390 people, headquartered in CAMBRIDGE, Massachusetts. With a market capitalization of $2.0B, AGIO is one of the notable companies in the Healthcare sector.

AGIOS PHARMACEUTICALS, INC. (AGIO) Stock Rating — Hold (April 2026)

As of April 2026, AGIOS PHARMACEUTICALS, INC. receives a Hold rating with a composite score of 31.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.AGIO ranks #1,735 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AGIOS PHARMACEUTICALS, INC. ranks #175 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AGIO Stock Price and 52-Week Range

AGIOS PHARMACEUTICALS, INC. (AGIO) currently trades at $32.92. The 52-week high for AGIO is $46.00, which means the stock is currently trading -28.4% from its annual peak. The 52-week low is $22.24, putting the stock 48.0% above its annual trough. Recent trading volume was 765K shares, suggesting relatively thin trading activity.

Is AGIO Overvalued or Undervalued? — Valuation Analysis

AGIOS PHARMACEUTICALS, INC. (AGIO) carries a value factor score of 18/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 3.20x, compared to the Healthcare sector average of 23.63x — a discount of 86%. The price-to-book ratio stands at 1.72x, versus the sector average of 2.75x. The price-to-sales ratio is 47.81x, compared to 1.66x for the average Healthcare stock.

At current multiples, AGIOS PHARMACEUTICALS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AGIOS PHARMACEUTICALS, INC. Profitability — ROE, Margins, and Quality Score

AGIOS PHARMACEUTICALS, INC. (AGIO) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 53.9%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 49.6% versus the sector average of -33.1%.

On a margin basis, AGIOS PHARMACEUTICALS, INC. reports gross margins of 88.0%, compared to 71.5% for the sector. The operating margin is -1074.1% (sector: -66.1%). Net profit margin stands at 1962.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 49.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AGIO Debt, Balance Sheet, and Financial Health

AGIOS PHARMACEUTICALS, INC. has a debt-to-equity ratio of 9.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 11.46x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $93M.

AGIO has a beta of 0.91, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for AGIOS PHARMACEUTICALS, INC. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

AGIOS PHARMACEUTICALS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, AGIOS PHARMACEUTICALS, INC. reported revenue of $43M and earnings per share (EPS) of $-7.12. Net income for the quarter was $643M. Gross margin was 88.0%. Operating income came in at $-453M.

In FY 2025, AGIOS PHARMACEUTICALS, INC. reported revenue of $54M and earnings per share (EPS) of $-7.12. Net income for the quarter was $-413M. Gross margin was 88.3%. Revenue grew 48.0% year-over-year compared to FY 2024. Operating income came in at $-472M.

In Q3 2025, AGIOS PHARMACEUTICALS, INC. reported revenue of $13M and earnings per share (EPS) of $-1.78. Net income for the quarter was $-103M. Gross margin was 87.0%. Revenue grew 43.7% year-over-year compared to Q3 2024. Operating income came in at $-117M.

In Q2 2025, AGIOS PHARMACEUTICALS, INC. reported revenue of $12M and earnings per share (EPS) of $-1.93. Net income for the quarter was $-112M. Gross margin was 86.3%. Revenue grew 44.6% year-over-year compared to Q2 2024. Operating income came in at $-127M.

Over the past 8 quarters, AGIOS PHARMACEUTICALS, INC. has demonstrated a growth trajectory, with revenue expanding from $9M to $43M. Investors analyzing AGIO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AGIO Dividend Yield and Income Analysis

AGIOS PHARMACEUTICALS, INC. (AGIO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AGIO Momentum and Technical Analysis Profile

AGIOS PHARMACEUTICALS, INC. (AGIO) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 57/100 reflects moderate short selling activity.

AGIO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AGIOS PHARMACEUTICALS, INC. (AGIO) ranks #175 out of 838 stocks based on the Blank Capital composite score. This places AGIO in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AGIO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AGIO vs S&P 500 (SPY) comparison to assess how AGIOS PHARMACEUTICALS, INC. stacks up against the broader market across all factor dimensions.

AGIO Next Earnings Date

No upcoming earnings date has been announced for AGIOS PHARMACEUTICALS, INC. (AGIO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AGIO? — Investment Thesis Summary

AGIOS PHARMACEUTICALS, INC. presents a balanced picture with arguments on both sides. The quality score of 25/100 flags below-average profitability. The value score of 18/100 indicates premium valuation. High volatility (stability score 35/100) increases portfolio risk.

In summary, AGIOS PHARMACEUTICALS, INC. (AGIO) earns a Hold rating with a composite score of 31.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AGIO stock.

Related Resources for AGIO Investors

Explore more research and tools: AGIO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AGIO head-to-head with peers: AGIO vs AZN, AGIO vs SLGL, AGIO vs VMD.